Answers are grounded in this paper and cite their sources.
Eflornithine (Iwilfin – US WorldMeds), an oral ornithine decarboxylase inhibitor, has been approved by the FDA to reduce the risk of relapse in children and with high-risk neuroblastoma who had at least a partial response to prior multiagent, multimodality therapy, including anti-GD2 immunotherapy.
No takes yet. Share an insight, caveat, or question.
A 2024 study studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: